Fruquintinib Renal Impairment Study

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

June 26, 2023

Study Completion Date

June 26, 2023

Conditions

Renal Impairment

Interventions

DRUG

Fruquintinib

Fruquintinib will be administered as a single dose on the morning of Day 1 under fasting conditions

Trial Locations (2)

Orlando Clinical Research Center, Orlando

Clinical Pharmacology of Miami, Miami